Posted by Michael Wonder on 18 Oct 2021
Oyster Point Pharma announces FDA approval of Tyrvaya (varenicline solution) nasal spray for the treatment of the signs and symptoms of dry eye disease
18 October 2021 - Tyrvaya is the first and only nasal spray approved for the treatment of the signs and symptoms of dry eye disease.
Oyster Point Pharma today announced that the U.S. FDA has approved Tyrvaya (varenicline solution) 0.03 mg nasal spray for the treatment of the signs and symptoms of dry eye disease.
